CEACAM1 expression has been reported to be lower in various carcinomas, such as urinary bladder cancer, renal cell carcinomas, and prostate cancer, as compared to nontumor tissue [13–15]. This evidence concerns the gene CEACAM1 and prostate carcinoma.